We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-6.35%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11.4B
AUM Growth
-$782M
Cap. Flow
+$157M
Cap. Flow %
1.38%
Top 10 Hldgs %
87.68%
Holding
124
New
6
Increased
21
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$234M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$100M
3
ASND icon
Ascendis Pharma A/S
ASND
+$10.6M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$9.37M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$6.88M

Top Sells

Rank Stock Value
1
ACOR
Acorda Therapeutics
ACOR
+$69.3M
2
DERM
Dermira, Inc.
DERM
+$14.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$13.5M
4
EXEL icon
Exelixis
EXEL
+$11M
5
CERS icon
Cerus
CERS
+$9M

Sector Composition

Rank Sector Weight
1 Healthcare 92.56%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMGN
26
DELISTED
Immunogen Inc
IMGN
$21.4M 0.19%
3,015,353
– –
PGNX
27
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$21.4M 0.19%
3,150,808
– –
HALO icon
28
Halozyme
HALO
$9.88B
$20.3M 0.18%
1,581,424
+189,917
+14% +$2.54M
LKFT
29
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$19.9M 0.17%
259,894
– –
XNCR icon
30
Xencor
XNCR
$1.45B
$18.4M 0.16%
872,072
– –
MRUS
31
DELISTED
Merus
MRUS
$18.4M 0.16%
1,160,014
– –
ACGN
32
DELISTED
Aceragen Inc
ACGN
$17.7M 0.15%
75,774
+62
+0.1% +$16.2K
NDRM
33
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$17.1M 0.15%
571,667
– –
NTLA icon
34
Intellia Therapeutics
NTLA
$1.51B
$17M 0.15%
1,062,120
– –
SAGE
35
DELISTED
Sage Therapeutics
SAGE
$16.6M 0.15%
208,328
– –
AERI
36
DELISTED
Aerie Pharmaceuticals
AERI
$15.7M 0.14%
299,356
– –
LJPC
37
DELISTED
La Jolla Pharmaceutical Company
LJPC
$15M 0.13%
504,732
+125,598
+33% +$3.6M
CPRX
38
DELISTED
Catalyst Pharmaceutical
CPRX
$14.1M 0.12%
5,102,153
– –
AIMT
39
DELISTED
Aimmune Therapeutics
AIMT
$13.9M 0.12%
673,908
– –
ARRY
40
DELISTED
Array Biopharma Inc
ARRY
$13.3M 0.12%
1,585,913
– –
FOMX
41
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$11.4M 0.1%
2,466,702
– –
LOXO
42
DELISTED
Loxo Oncology, Inc
LOXO
$11.1M 0.1%
138,312
+577
+0.4% +$32K
ABEO icon
43
Abeona Therapeutics
ABEO
$355M
$10.8M 0.09%
67,375
– –
RXDX
44
DELISTED
Ignyta, Inc.
RXDX
$9.27M 0.08%
896,000
+325,000
+57% +$2.64M
SYRS
45
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$9.25M 0.08%
57,484
+37,037
+181% +$5.82M
LGND icon
46
Ligand Pharmaceuticals
LGND
$5.77B
$8.91M 0.08%
117,638
– –
ALKS icon
47
Alkermes
ALKS
$8.11B
$8.71M 0.08%
150,251
– –
ACHN
48
DELISTED
Achillion Pharmaceuticals
ACHN
$8.52M 0.07%
1,856,637
– –
MRTX
49
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.28M 0.07%
2,269,198
– –
ITCI
50
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$7.57M 0.07%
609,166
– –
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Baker Bros. Advisors held 124 positions worth $11.4B, down 6.4% from $12.2B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Baker Bros. Advisors's Q2 2017 filing shows 6 new, 21 increased, 9 reduced and 4 closed positions. Its largest new stake was Lumos Pharma, Inc. Common Stock: 55,556 shares worth $3.67M. The largest sale was Acorda Therapeutics, an estimated $69.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q2 2017 buy was Lumos Pharma, Inc. Common Stock: 55,556 shares worth $3.67M.
  • Baker Bros. Advisors added most to Alexion Pharmaceuticals in Q2 2017, an estimated $234M increase.
  • Baker Bros. Advisors's biggest Q2 2017 reduction was Neurocrine Biosciences, cutting an estimated $13.5M.
  • Baker Bros. Advisors fully exited Acorda Therapeutics in Q2 2017, selling an estimated $69.3M.
  • Baker Bros. Advisors's ten largest holdings make up 88% of its $11.4B portfolio in Q2 2017.
  • Baker Bros. Advisors opened 6 new positions and closed 4 in Q2 2017.
  • Baker Bros. Advisors's portfolio value fell 6.4% quarter-over-quarter to $11.4B.

Based on Baker Bros. Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.